Anti-PARL monoclonal antibody
Pre-made anti-PARL monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to PARL/PARL products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1325-Ab-1/ GM-Tg-hg-IP1325-Ab-2 | Anti-Human PARL monoclonal antibody | Human |
GM-Tg-rg-IP1325-Ab-1/ GM-Tg-rg-IP1325-Ab-2 | Anti-Rat PARL monoclonal antibody | Rat |
GM-Tg-mg-IP1325-Ab-1/ GM-Tg-mg-IP1325-Ab-2 | Anti-Mouse PARL monoclonal antibody | Mouse |
GM-Tg-cynog-IP1325-Ab-1/ GM-Tg-cynog-IP1325-Ab-2 | Anti-Cynomolgus/ Rhesus macaque PARL monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1325-Ab-1/ GM-Tg-felg-IP1325-Ab-2 | Anti-Feline PARL monoclonal antibody | Feline |
GM-Tg-cang-IP1325-Ab-1/ GM-Tg-cang-IP1325-Ab-2 | Anti-Canine PARL monoclonal antibody | Canine |
GM-Tg-bovg-IP1325-Ab-1/ GM-Tg-bovg-IP1325-Ab-2 | Anti-Bovine PARL monoclonal antibody | Bovine |
GM-Tg-equg-IP1325-Ab-1/ GM-Tg-equg-IP1325-Ab-2 | Anti-Equine PARL monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP1325-Ab-1/ GM-Tg-hg-IP1325-Ab-2; GM-Tg-rg-IP1325-Ab-1/ GM-Tg-rg-IP1325-Ab-2; GM-Tg-mg-IP1325-Ab-1/ GM-Tg-mg-IP1325-Ab-2; GM-Tg-cynog-IP1325-Ab-1/ GM-Tg-cynog-IP1325-Ab-2; GM-Tg-felg-IP1325-Ab-1/ GM-Tg-felg-IP1325-Ab-2; GM-Tg-cang-IP1325-Ab-1/ GM-Tg-cang-IP1325-Ab-2; GM-Tg-bovg-IP1325-Ab-1/ GM-Tg-bovg-IP1325-Ab-2; GM-Tg-equg-IP1325-Ab-1/ GM-Tg-equg-IP1325-Ab-2 |
Products Name | Anti-PARL monoclonal antibody |
Format | mab |
Target Name | PARL |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-PARL monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP1325-Ag-1 | Recombinant multi-species PARL/ PRO2207/ PSARL protein |
ORF Viral Vector | pGMLP004196 | human PARL Lentivirus plasmid |
ORF Viral Vector | vGMLP004196 | human PARL Lentivirus particle |
Target information
Target ID | GM-IP1325 |
Target Name | PARL |
Gene ID | 55486,381038,287979,704652,488100,101091042,514191,100058851 |
Gene Symbol and Synonyms | D16Ertd607e,PARL,PRO2207,PSARL,PSARL1,PSENIP2,RHBDS1 |
Uniprot Accession | Q9H300,Q3B8P0,Q2KHV4 |
Uniprot Entry Name | PARL_HUMAN,PARL_RAT,PARL_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000175193 |
Target Classification | N/A |
The target: PARL, gene name: PARL, also named as PRO2207, PSARL, PSARL1, PSENIP2, RHBDS1. This gene encodes a member of the rhomboid family of intramembrane serine proteases that is localized to the inner mitochondrial membrane. The encoded protein regulates mitochondrial remodeling and apoptosis through regulated substrate proteolysis. Proteolytic processing of the encoded protein results in the release of a small peptide, P-beta, which may transit to the nucleus. Mutations in this gene may be associated with Parkinson's disease. [provided by RefSeq, May 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.